Accessibility Menu
Aida Pharmaceuticals logo

Aida Pharmaceuticals(OTC) AIDA

Market Cap$8.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-98%
1 Year+51%
1 Month+51%
$0.00
+0%
+0.00Today
Aida Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002025-12-30
Aida Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+50.5%USD 0.002025-12-10
1 month+50.5%USD 0.002025-08-05
3 month+50.5%USD 0.002025-08-05
Year to date+50.5%USD 0.002024-12-18
1 year+50.5%USD 0.002024-12-18
3 year+0.33%USD 0.002022-10-26
5 year-97.85%USD 0.012020-12-31
Since inception-99.98%USD 1.452005-12-16

Aida Pharmaceuticals Financials at a Glance

Market Cap

$8.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$40.95M

Net Income (TTM)

-$2.09M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-4.34 (Low)

Price

$0.00

Volume

500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

AIDA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aida Pharmaceuticals

Aida Pharmaceuticals, Inc. is a healthcare company based in Hangzhou, China, specializing in pharmaceutical and genetic product development. Established in 1999, the company offers a diverse range of products, including antibiotics, cardiovascular medicines, and anti-cancer drugs.

Products and Services
  • Injectable powders and intravenous liquids
  • Capsules, tablets, and ointments
  • Notable products include Etimicin Sulfate and rh-Apo2l
Growth Outlook
  • Significant market presence in mainland China enhances growth potential
  • Focus on innovative biopharmaceutical therapies for cancer treatment
  • Expansion of product offerings to meet diverse healthcare needs
Financial Highlights
  • Recent quarterly revenue of 11.9 million USD, showing strong performance
  • Net income of 2.29 million USD in the latest quarter
  • Trailing twelve months (TTM) gross profit margin of 50.31%
Aida Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, leveraging its extensive experience in formulation, clinical trials, regulatory registration, and marketing. The company has demonstrated resilience with a recent quarterly revenue of 11.9 million USD, reflecting a robust demand for its products. The net income of 2.29 million USD in the latest quarter indicates effective cost management and operational efficiency. With a TTM gross profit margin of 50.31%, Aida Pharmaceuticals showcases its ability to maintain profitability while navigating the competitive pharmaceutical landscape. The company's strategic focus on innovative therapies and expansion into new markets positions it well for future growth.
AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Hangzhou, ZH 310016, CN

AIDA Financials

Key Financial Metrics (TTM)

Gross Margin

50.31%

Operating Margin

18.64%

Net Income Margin

9.38%

Return on Equity

23.15%

Return on Capital

11.66%

Return on Assets

4.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.00M

Volume

500

Avg. Volume

0

Financials (TTM)

Gross Profit

$22.79M

Operating Income

$12.95M

EBITDA

$2.47M

Operating Cash Flow

$6.17M

Capital Expenditure

-$5.26M

Free Cash Flow

$911.25K

Cash & ST Invst.

$9.98M

Total Debt

$41.16M

Aida Pharmaceuticals Performance Analysis

Aida Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42007-12-3142.6%
Q12008-03-31-27.2%
Q22008-06-3042.4%
Q32008-09-309.0%
Aida Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42007-12-31350.0%
Q12008-03-31-100.8%
Q22008-06-30-35614.3%
Q32008-09-30132.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2008YOY CHG

Revenue

$11.89M

+61.2%

Gross Profit

$6.93M

+81.5%

Gross Margin

58.28%

N/A

Market Cap

$8.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$18.00

N/A

Employees

450

N/A

Net Income

$2.29M

+341.2%

EBITDA

$3.36M

+76.7%

Quarterly Fundamentals

Name
Q3 2008YOY CHG

Total Cash

$9.98M

+29.7%

Total Debt

$41.16M

+26.0%

Accounts Receivable

$12.31M

-1.7%

Inventory

$5.47M

+32.4%

Long Term Debt

$8.61M

+348.0%

Short Term Debt

$32.55M

+5.9%

Return on Assets

4.37%

N/A

Return on Invested Capital

22.82%

N/A

Free Cash Flow

-$403.99K

-114.4%

Operating Cash Flow

$2.15M

-51.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
UPPRUpper Street Marketing Inc.
$0.00+0.00%
CENBFCEN Biotech, Inc.
$0.00+0.00%
BTTXBetter Therapeutics, Inc.
$0.00+0.00%
PANCPanacos Pharmaceuticals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About AIDA

What is the current price of Aida Pharmaceuticals?

Aida Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Aida Pharmaceuticals?

Over the past 52 weeks, Aida Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Aida Pharmaceuticals have?

Aida Pharmaceuticals total debt is unavailable.

How much cash does Aida Pharmaceuticals have on hand?

Aida Pharmaceuticals does not have cash on hand data available.

What is Aida Pharmaceuticals’s dividend yield?

Aida Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services